BRAIN METASTASIS AND HER-2 STATUS IN METASTATIC BREAST CANCER (MBC) IN OMAN

被引：0
|
作者：
Monem, E. Abdul [1 ]
Mehdi, I. [1 ]
Al Bahrani, B. [1 ]
机构：
[1] Royal Hosp, Muscat, Oman
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
121P
引用
收藏
页码：48 / 48
页数：1
相关论文
共 50 条
  • [41] Drug Holidays in Patients with HER-2 Positive Metastatic Breast Cancer
    Kurtom, Saba
    Senol, Kazim
    Sabih, Qurat Ul Ain
    Sezgin, Efe
    Brufsky, Adam
    Gorantla, Vikram
    Puhalla, Shannon
    Soran, Atilla
    CANCER RESEARCH, 2024, 84 (09)
  • [42] Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer
    Mokhtari, Maral
    Khosravi, Mohammad Hadi
    MIDDLE EAST JOURNAL OF CANCER, 2021, 12 (04) : 483 - 490
  • [43] HER2-positive (HER2+) metastatic breast cancer (MBC) presentation and patterns of progression
    Di Cosimo, Serena
    Serpico, Danila
    Porcu, Luca
    Tessari, Anna
    Molino, Leonardo
    Torri, Valter
    de Braud, Filippo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Efficacy it eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled Analysis by HER2 and ER status
    Kaufman, Peter
    Twelves, Chris
    Cortes, Javier
    Vandat, Linda T.
    Olivo, Martin
    He, Yi
    Awada, Ahmad
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [45] Circulating tumor cells (CTCs) detect HER2+status and phenotypic heterogeneity in metastatic breast cancer (MBC)
    Austin, Laura
    Mu, Zhaomei
    Avery, Tiffany
    Jaslow, Rebecca
    Paolillo, Carmela
    Toss, Angela
    Fortuna, Paolo
    Zhong, Ye
    Yang, Hushan
    Cristofanilli, Massimo
    CANCER RESEARCH, 2015, 75
  • [46] Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status
    Twelves, C.
    Cortes, J.
    Vahdat, L.
    Olivo, M.
    He, Y.
    Kaufman, P. A.
    Awada, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 261 - 262
  • [47] EGFR activity in Her-2 overexpressing metastatic breast cancer: evidence for simultaneous phosphorylation of Her-2/neu and EGFR
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 132 - 132
  • [48] EVOLUTION OF CHEMOTHERAPY OPTIONS IN HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Verma, S.
    Zielinski, C.
    Martin, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 98 - 99
  • [49] Gemcitabine, vinorelbine and trastuzumab combination (GemVinT) as second-third line therapy for HER-2 overexpressing metastatic breast cancer (MBC).
    Morabito, A
    Carillio, G
    Bonginelli, P
    Amici, S
    Longo, R
    Sarmiento, R
    Fanelli, M
    Stani, SC
    Gattuso, D
    Gasparini, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 66S - 66S
  • [50] Long term survival and incidence of brain metastasis in HER2-positive (HER2+) metastatic breast cancer patients (MBC) treated with trastuzumab (T): an institutional based review
    Dieras, V.
    Guilhaume, M. N.
    Fall, M.
    Pierga, J. Y.
    Beuzeboc, P.
    Cottu, P.
    Simondi, C.
    Courbard, M.
    Mignot, M.
    Livartowski, A.
    EJC SUPPLEMENTS, 2010, 8 (03): : 202 - 203
12345